A Phase 3, Randomized, Open-label Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined with Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence (PIVOT-12)

  • Wang, Peng (PI)

Grants and Contracts Details

StatusActive
Effective start/end date2/17/217/10/23